Sleep Disorder, Stroke, Ischemic
Conditions
Keywords
neuroplasticity, cognitive dysfunction, disability, circadian rhythm, functional deficit, stroke outcome, sleep-disordered breathing, heart rate variability
Brief summary
The study is aimed at the investigation of the association of biomarkers of circadian rhythms with sleep characteristics and stroke outcome in acute stroke patients. It is designed as an observational cohort study with the retrospective and prospective longitudinal arms.
Detailed description
In the retrospective arm of the study, the routinely collected data of patients admitted to the stroke unit with acute ischemic stroke (from 2018 till 2022) will be evaluated. In the prospective longitudinal arm, about 200-250 patients admitted to the Stroke Unit of one participating center will undergo examination including the assessment of medical records, stroke characteristics, sleep characteristics and blood sampling for the evaluation of genetic biomarkers of circadian rhythms within the first 2-3 days after admission.The assessment of stroke severity and functional deficit will be repeated at 10-14 days after stroke. The following associations will be assessed: * the association of genetic biomarkers of circadian rhythms with stroke outcome (the difference in neurological and functional deficit from admission to 14th day after stroke), with stroke characteristics (stroke subtype and neuroimaging stroke parameters) and with sleep characteristics. * the association of sleep characteristics with stroke outcome (the difference in neurological and functional deficit from admission to 14th day after stroke) and with stroke characteristics (stroke subtype and neuroimaging stroke parameters).
Interventions
No intervention is planned
Sponsors
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* acute (symptom onset to admission \<1 days) ischemic stroke * ischemic stroke affecting the branches of anterior cerebral artery, middle cerebral artery and posterior cerebral artery * age 18-80 years * moderate or severe stroke (National Institutes of Health Stroke Scale, NIHSS\>=5) * intravascular stroke treatment with thrombolysis or thrombectomy leading to satisfactory reperfusion (if applicable) * informed consent
Exclusion criteria
* secondary parenchymal hemorrhage (\>hemorrhage index -2) * clinically unstable or life-threatening conditions * known progressive neurological diseases * known psychiatric diseases * concomitant benzodiazepine medication * drug or alcohol abuse * pregnancy * disability to participate in the study * congestive heart failure with reduced ejection fraction (\<=45%) or New York Heart Association (NYHA) classification III-IV functional class
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the value of National Institutes of Health Stroke Scale from baseline to 14th day after inclusion | From baseline to 14th day after treatment initiation | National Institutes of Health Stroke Scale (NIHSS) is a tool used to objectively quantify the impairment caused by a stroke, 0-42 scores, higher scores characterize worse impairment |
| Stroke-related disability assessed by the change in modified Rankin scale from baseline to 14th day after treatment initiation | From baseline to 14th day after treatment initiation | values of modified Rankin scale (scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke, from 0 (no symptoms) to 6 (dead) points) |
| Stroke-related disability assessed by the change in Rivermead Mobility Index from baseline to 14th day after treatment initiation | From baseline to 14th day after treatment initiation | a standardized scale used to assess mobility in patients with neurological deficits, a maximum of 15 points is possible; higher scores indicate better mobility performance |
| Stroke-related disability assessed by the change in Barthel Index from baseline to 14th day after treatment initiation | From baseline to 14th day after treatment initiation | a common scale used to measure performance in activities of daily living, 0-100 scores, higher scores define better performance |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sleep quality assessed by Pittsburgh Sleep Quality Index | Baseline | Pittsburgh Sleep Quality Index is a self-rated questionnaire which assesses sleep quality and disturbances over the last (previous) 1-month (a retrospective assessment) time interval, Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score indicating worse sleep quality |
| Chronotype assessed by Morningness-Eveningness Questionnaire | Baseline | a common 19-item tool to estimate individual chronotype, a score ranging from 16 to 86; scores of 41 and below indicate evening types, scores of 59 and above indicate morning types, scores between 42-58 indicate intermediate types |
| Sleepiness assessed by Epworth Sleepiness Scale | Baseline | a common tool to assess sleepiness; 0-24 points, higher score indicate greater sleepiness |
| Fatigue assessed by Fatigue severity Scale | Baseline | a common 9-item tool used to determine and quantify fatigue as subjective feeling of exhaustion, persisting lack of energy and rapid inanition, 9-63 points, higher score indicates more severe fatigue |
| Insomnia assessed by Insomnia severity index | Baseline | a 7-item tool to assess the severity of insomnia, 0-5 points per each item, higher score indicates more severe insomnia |
Other
| Measure | Time frame | Description |
|---|---|---|
| Nocturnal heart rate variability characteristics derived from nocturnal pulseoximeter data: standard deviation of normal-to-normal intervals | Baseline | standard deviation of normal-to-normal intervals (msec) |
| Nocturnal heart rate variability characteristics derived from nocturnal pulseoximeter data: number of interval differences of successive heart beats greater than 50 ms | Baseline | number of interval differences of successive heart beats greater than 50 ms |
| Nocturnal heart rate variability characteristics derived from nocturnal pulseoximeter data: spectral power in high-frequency power bands | Baseline | spectral power in high-frequency power bands (Hz) |
| Nocturnal heart rate variability characteristics derived from nocturnal pulseoximeter data: spectral power in low-frequency power bands | Baseline | spectral power in low-frequency power bands (Hz) |
| Sleep duration assessed by polysomnography | Baseline | Sleep duration (minutes) |
| Wake after sleep onset time assessed by polysomnography | Baseline | wake after sleep onset time (minutes), higher values indicate worse disturbance |
| Sleep latency assessed by polysomnography | Baseline | sleep latency (minutes) |
| Sleep S1 stage duration assessed by polysomnography | Baseline | S1 sleep stage percentage of total sleep time (%) |
| Sleep S2 stage duration assessed by polysomnography | Baseline | S2 sleep stage percentage of total sleep time (%) |
| Sleep S3 stage duration assessed by polysomnography | Baseline | S3 sleep stage percentage of total sleep time (%) |
| Stroke lesion volume | Baseline | Stroke lesion volume assessed by neuroimaging (computer tomography scan or magnetic resonance imaging) (ml or mm3) |
| Sleep efficiency assessed by polysomnography | Baseline | sleep efficiency (%) |
| Arousal index assessed by polysomnography | Baseline | Arousal index (episodes/hour of sleep), higher values indicate worse disturbance |
| periodic limb movement index assessed by polysomnography | Baseline | periodic limb movement index (episodes/hour of sleep), higher values indicate worse disturbance |
| Rapid eye movement (REM) stage duration assessed by polysomnography | Baseline | Rapid eye movement (REM) sleep stage percentage of total sleep time (%) |
| sleep-related respiratory characteristics: apnea-hypopnea index | Baseline | assessed by routine polygraphy: apnea-hypopnea index (higher values indicate greater severity; \<5 episodes/h - normal, \>=5 episodes/h - pathological) |
| sleep-related respiratory characteristics: oxygen desaturation index | Baseline | assessed by routine polygraphy: oxygen desaturation index (higher values indicate greater severity; \<5 episodes/h - normal, \>=5 episodes/h - pathological) |
| sleep-related respiratory characteristics: time under oxygen saturation <90% | Baseline | assessed by routine polygraphy: time under oxygen saturation \<90% (higher values indicate greater severity), in minutes |
| sleep-related respiratory characteristics: average oxygen saturation | Baseline | assessed by routine polygraphy: average oxygen saturation (lower values indicate greater severity), in % |
| sleep-related respiratory characteristics: lowest oxygen saturation | Baseline | assessed by routine polygraphy: lowes oxygen saturation (lower values indicate greater severity), in % |
Countries
Russia
Contacts
Primary ContactLyudmila Korostovtseva, MD, PHD
Outcome results
None listed